Meeting
2024 ASCO Annual Meeting
Glucagon-like peptide-1 (GLP-1) agonist use and weight change among patients with breast cancer.
Authors
Sherry Shen
Memorial Sloan Kettering Cancer Center, New York, NY
Sherry Shen , Bethina Liu , Chad Fanti , Maria Bromberg , Yuan Chen , Cassandra Chang , Neil M. Iyengar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Genetics
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Health Promotion/Behaviors
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 10607)
DOI
10.1200/JCO.2024.42.16_suppl.10607
Abstract #
10607
Poster Bd #
134
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Mediation of black/white disparities in triple negative breast cancer by socioeconomic position, reproductive factors and diabetes in the Nurses’ Health Study Cohorts I & II.
First Author: Lydia Marcus
Poster
2020 ASCO Virtual Scientific Program
Predictor of trastuzumab-induced cardiotoxicity in breast cancer (BC) patients: HER2/neu 655 polymorphisms, biochemical and clinical features.
First Author: Isabel Blancas
Poster
2018 Cancer Survivorship Symposium
Analysis of weight trends over time in female survivors with triple negative breast cancer.
First Author: Damien Mikael Hansra
Poster
2015 Breast Cancer Symposium
Impact of breast cancer treatment on body mass index (BMI) over time.
First Author: Raquel E. Reinbolt